

Amendments to the claims:

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of claims:

Claims 1-29 (canceled).

30 (new): A compound comprising a structural entity, wherein the structural entity binds or is an antagonist for interleukin-6 (IL-6), and/or the IL-6 receptor, and/or part of the IL-6 receptor, and wherein the compound depletes IL-6 from a solution, or blocks at least one or more IL-6 functions on cell surfaces, or blocks at least one or more IL-6 functions in a solution.

31 (new): The compound of claim 30 wherein the IL-6, the IL-6 receptor, or part of the IL-6 receptor is the human IL-6, the human IL-6 receptor, or part of the human IL-6 receptor.

32 (new): The compound of claim 30, wherein the solution is a body fluid or obtained from a tissue.

33 (new): The compound of claim 30, wherein the solution is blood.

- 34 (new): The compound of claim 30, wherein the compound is a polypeptide containing a binding site for IL-6 and/or the IL-6 receptor.
- 35 (new): The compound of claim 30, wherein the compound is an antibody containing an antigen-binding site for IL-6 and/or the IL-6 receptor.
- 36 (new): The compound of claim 30, wherein the compound is a monoclonal antibody containing an antigen-binding site for IL-6 and/or the IL-6 receptor.
- 37 (new): The compound of claim 30, wherein the compound is a monoclonal antibody containing an antigen-binding site for IL-6 and/or the IL-6 receptor, wherein the monoclonal antibody is a recombinant antibody.
- 38 (new): The compound of claim 30, wherein the compound is a monoclonal antibody containing an antigen-binding site for IL-6 and/or the IL-6 receptor, wherein the monoclonal antibody is a recombinant single chain scAb or scFv antibody, a bispecific antibody, or a diabody.
- 39 (new): The compound of claim 30, wherein the compound is a monoclonal antibody containing an antigen-binding site for IL-6 and/or the IL-6 receptor, wherein the monoclonal antibody is a recombinant single chain scAb or scFv antibody, a bispecific antibody, or a diabody capable of

binding to IL-6 and/or the IL-6 receptor by containing the antigen-binding site of an antibody which is cross-reactive with IL-6 and/or the IL-6 receptor.

40 (new): A nucleic acid comprising nucleotide sequences encoding the compound of claim 30.

41 (new): A recombinant vector comprising the nucleic acid of claim 40 operably linked to regulating sequences capable of expressing the compound in a host cell.

42 (new): The recombinant vector of claim 41, wherein the compound is an antibody.

43 (new): A host cell comprising the vector according to claim 41.

44 (new): The host cell of claim 43, wherein the compound is an antibody.

45 (new): The host cell of claim 44 from a prokaryotic cell line.

46 (new): The host cell of claim 44 from a eukaryotic cell line.

47 (new): The host cell of claim 44 from a non-human eukaryotic organism.

48 (new): A method comprising culturing the host cell of claim 43 in a culture medium and isolating the compound from the culture medium and/or the host cell.

49 (new): The compound of claim 30, wherein the compound is a recombinant polypeptide.

50 (new): A medicament for treating an endothelial disorder or an immune disorder excluding arthritis comprising

- a) a therapeutically effective amount of the compound of claim 30 in combination with
- b) a pharmacologically acceptable carrier.

51 (new): The medicament of claim 50 further comprising

- c) an anti-inflammatory substance selected from the group consisting of C-reactive Protein (CRP) antagonists, CRP binding molecules, anti-IL-1 β -molecules, PLA2 antagonists, PLA2 binding molecules, complement blockers, and combinations thereof.

52 (new): A method for treating an endothelial disorder or an immune disorder excluding rheumatoid arthritis comprising administering to a patient in need thereof an effective amount of the compound of claim 30.

53 (new): The method of claim 52 for treating an endothelial disorder excluding rheumatoid arthritis, wherein the endothelial disorder is selected from the group consisting of stroke, cardiac infarction, avoidance of sudden cardiac death, atherosclerosis with unstable angina, acute liver failure, and hormone replacement therapy (HRT), and wherein the immune disorder is selected from the group consisting of radiation-induced leukemia, allograft transplant rejection, xeno-transplant rejection, inhibition of T cell activation, HIV infection, AIDS, autoimmune disease, autoimmune liver disease, diabetes type I and type II, osteoarthritis, neurodegenerative disease, Graves' disease, Hashimoto disease, dilated cardiomyopathy, diabetes mellitus, Morbus Bechterew, inflammatory bile disease, ulcerative colitis, idiopathic thrombocytopenia purpura (ITP), aplastic anemia, idiopathic dilated cardiomyopathy (IDM), autoimmune thyroiditis, Goodpastures' disease, diabetic shock, and combinations thereof.

54 (new): The method of claim 52 for treating an immune disorder, wherein the immune disorder is myasthenia gravis.

55 (new): A method of treatment for inhibiting immunologic, inflammatory, and/or patho-physiological responses comprising administering to a patient in need thereof an effective amount of the compound of claim 30.

56 (new): A method for reducing IL-6 concentration and/or unoccupied IL-6 receptor concentration comprising administering to a patient in need thereof an effective amount of the compound of claim 30.